Data as of Aug 29
| -0.009 / -2.25%|
The 1 analysts offering 12-month price forecasts for Boston Therapeutics Inc have a median target of 1.80, with a high estimate of 1.80 and a low estimate of 1.80. The median estimate represents a +360.36% increase from the last price of 0.39.
The current consensus among 1 polled investment analysts is to Buy stock in Boston Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.